Full Text:   <396>

Summary:  <99>

CLC number: 

On-line Access: 2024-02-01

Received: 2023-04-09

Revision Accepted: 2023-07-21

Crosschecked: 2024-02-02

Cited: 0

Clicked: 611

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Ahmad ALHASKAWI

https://orcid.org/0000-0001-8122-592X

Sohaib Hasan Abdullah EZZI

https://orcid.org/0000-0002-6080-6239

Hui LU

https://orcid.org/0000-0002-5921-1043

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2024 Vol.25 No.2 P.106-122

http://doi.org/10.1631/jzus.B2300221


Recent advancements in the diagnosis and treatment of acral melanoma


Author(s):  Ahmad ALHASKAWI, Sohaib Hasan Abdullah EZZI, Yanzhao DONG, Haiying ZHOU, Zewei WANG, Jingtian LAI, Chengjun YAO, Vishnu Goutham KOTA, Mohamed Hasan Abdulla Hasan ABDULLA, Hui LU

Affiliation(s):  Department of Orthopedics, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China; more

Corresponding email(s):   huilu@zju.edu.cn

Key Words:  Acral melanoma, Acral lentiginous melanoma, Acral nevus, Cutaneous malignant melanoma, Dermoscopy, Oncolytic virotherapy


Ahmad ALHASKAWI, Sohaib Hasan Abdullah EZZI, Yanzhao DONG, Haiying ZHOU, Zewei WANG, Jingtian LAI, Chengjun YAO, Vishnu Goutham KOTA, Mohamed Hasan Abdulla Hasan ABDULLA, Hui LU. Recent advancements in the diagnosis and treatment of acral melanoma[J]. Journal of Zhejiang University Science B, 2024, 25(2): 106-122.

@article{title="Recent advancements in the diagnosis and treatment of acral melanoma",
author="Ahmad ALHASKAWI, Sohaib Hasan Abdullah EZZI, Yanzhao DONG, Haiying ZHOU, Zewei WANG, Jingtian LAI, Chengjun YAO, Vishnu Goutham KOTA, Mohamed Hasan Abdulla Hasan ABDULLA, Hui LU",
journal="Journal of Zhejiang University Science B",
volume="25",
number="2",
pages="106-122",
year="2024",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2300221"
}

%0 Journal Article
%T Recent advancements in the diagnosis and treatment of acral melanoma
%A Ahmad ALHASKAWI
%A Sohaib Hasan Abdullah EZZI
%A Yanzhao DONG
%A Haiying ZHOU
%A Zewei WANG
%A Jingtian LAI
%A Chengjun YAO
%A Vishnu Goutham KOTA
%A Mohamed Hasan Abdulla Hasan ABDULLA
%A Hui LU
%J Journal of Zhejiang University SCIENCE B
%V 25
%N 2
%P 106-122
%@ 1673-1581
%D 2024
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2300221

TY - JOUR
T1 - Recent advancements in the diagnosis and treatment of acral melanoma
A1 - Ahmad ALHASKAWI
A1 - Sohaib Hasan Abdullah EZZI
A1 - Yanzhao DONG
A1 - Haiying ZHOU
A1 - Zewei WANG
A1 - Jingtian LAI
A1 - Chengjun YAO
A1 - Vishnu Goutham KOTA
A1 - Mohamed Hasan Abdulla Hasan ABDULLA
A1 - Hui LU
J0 - Journal of Zhejiang University Science B
VL - 25
IS - 2
SP - 106
EP - 122
%@ 1673-1581
Y1 - 2024
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2300221


Abstract: 
acral melanoma (AM) is the most common histologic subtype of melanoma in dark-skinned patients and is associated with a worse prognosis and a high mortality rate, largely due to the inconspicuous nature of early-stage lesions, which can lead to late diagnosis. Because of the overlapping clinical and histopathological features of AM with other forms of cutaneous melanomas, early detection of AM requires a multidisciplinary approach that integrates various diagnostic modalities, including clinical examination, dermoscopy, histopathology, molecular testing, radiological imaging, and blood tests. While surgery is the preferred method of treatment for AM, other therapeutic options may be employed based on the stage and underlying etiology of the disease. Immune checkpoint inhibitors, molecular targeted therapy, radiotherapy, chemotherapy, and oncolytic virotherapy represent promising advanced treatment options for AM. In this review, we provide an overview of the latest advancements in diagnostic and therapeutic methods for AM, highlighting the importance of early detection and the prompt, individualized management of this challenging disease.

肢端黑色素瘤的诊断和治疗进展

Ahmad ALHASKAWI1,Sohaib Hasan Abdullah EZZI2,董延钊1,周海英1,王泽伟3,来经天3,姚成俊3,Vishnu Goutham KOTA3,Mohamed Hasan Abdulla Hasan ABDULLA3,卢荟1,4
1浙江大学医学院附属第一医院骨科,中国杭州市,310003;
2中南大学湘雅三医院骨科,中国长沙市,410013;
3浙江大学医学院,中国杭州市,3100058;
4阿里巴巴-浙江大学未来数字医疗联合研究中心,中国杭州市,310058
摘要:肢端黑色素瘤(AM)是深色皮肤患者中最常见的黑色素瘤组织学亚型,常伴有更差的预后和高死亡率,主要原因为早期病变的不典型特征导致诊断延误。由于AM的临床和组织病理学特征与其他形式的皮肤黑色素瘤相近,其早期检测需要综合各种诊断模式的多学科方法,包括临床检查、皮肤镜检查、组织病理学检查、分子检测、放射学成像和血液检测。虽然手术是AM的首选治疗方法,但是根据疾病的分期和潜在病因,也可以采用其他治疗方案。免疫检查点抑制剂、分子靶向治疗、放疗、化疗和溶瘤病毒治疗在AM治疗上具有应用前景。在本文中,我们概述了AM诊断和治疗方法的最新进展,强调了早期发现和及时、个性化管理在这一具有挑战性疾病诊疗上的重要性。

关键词:肢端黑色素瘤;肢端雀斑样黑色素瘤;肢端痣;皮肤恶性黑色素瘤;皮肤镜检查;溶瘤病毒治疗

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]AbbasiNR, ShawHM, RigelDS, et al., 2004. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA, 292(22):2771-2776.

[2]AlemanyR, 2013. Viruses in cancer treatment. Clin Transl Oncol, 15(3):182-188.

[3]AndtbackaRHI, KaufmanHL, CollichioF, et al., 2015. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol, 33(25):2780-2788.

[4]ArasanzH, Gato-CañasM, ZuazoM, et al., 2017. PD1 signal transduction pathways in T cells. Oncotarget, 8(31):51936-51945.

[5]ArringtonJH III, ReedRJ, IchinoseH, et al., 1977. Plantar lentiginous melanoma: a distinctive variant of human cutaneous malignant melanoma. Am J Surg Pathol, 1(2):131-143.

[6]AsciertoPA, SchadendorfD, BerkingC, et al., 2013. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol, 14(3):249-256.

[7]BastianBC, 2014. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol: Mech Dis, 9:239-271.

[8]BeadlingC, Jacobson-DunlopE, HodiFS, et al., 2008. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res, 14(21):6821-6828.

[9]BeasleyGM, CaudleA, PetersenRP, et al., 2009. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg, 208(5):706-715.

[10]BelloDM, ChouJF, PanageasKS, et al., 2013. Prognosis of acral melanoma: a series of 281 patients. Ann Surg Oncol, 20(11):3618-3625.

[11]BianSX, HwangL, HwangJ, et al., 2021. Acral lentiginous melanoma—population, treatment, and survival using the NCDB from 2004 to 2015. Pigment Cell Melanoma Res, 34(6):1049-1061.

[12]BichakjianCK, HalpernAC, JohnsonTM, et al., 2011. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol, 65(5):1032-1047.

[13]BoydAS, RapiniRP, 1994. Acral melanocytic neoplasms: a histologic analysis of 158 lesions. J Am Acad Dermatol, 31(5 Pt 1):740-745.

[14]BradfordPT, GoldsteinAM, McMasterML, et al., 2009. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986‒2005. Arch Dermatol, 145(4):427-434.

[15]Bravo PuccioF, ChianC, 2011. Acral junctional nevus versus acral lentiginous melanoma in situ: a differential diagnosis that should be based on clinicopathologic correlation. Arch Pathol Lab Med, 135(7):847-852.

[16]BristowIR, de BerkerDAR, 2010. Development of a practical guide for the early recognition for malignant melanoma of the foot and nail unit. J Foot Ankle Res, 3:22.

[17]CabreraR, ReculeF, 2018. Unusual clinical presentations of malignant melanoma: a review of clinical and histologic features with special emphasis on dermatoscopic findings. Am J Clin Dermatol, 19(S1):15-23.

[18]CascinelliN, ZurridaS, GalimbertiV, et al., 1994. Acral lentiginous melanoma. A histological type without prognostic significance. J Dermatol Surg Oncol, 20(12):817-822.

[19]CastanedaCA, Torres-CabalaC, CastilloM, et al., 2017. Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America. Clin Transl Oncol, 19(12):1478-1488.

[20]ChangAE, KarnellLH, MenckHR, 1998. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer, 83(8):1664-1678.

[21]ChapmanPB, RobertC, LarkinJ, et al., 2017. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol, 28(10):2581-2587.

[22]ChesneyJ, PuzanovI, CollichioF, et al., 2018. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol, 36(17):1658-1667.

[23]ChuahSY, TsilikaK, ChiaveriniC, et al., 2015. Dermoscopic features of congenital acral melanocytic naevi in children: a prospective comparative and follow-up study. Br J Dermatol, 172(1):88-93.

[24]CinottiE, DebarbieuxS, PerrotJL, et al., 2016. Reflectance confocal microscopy features of acral lentiginous melanoma: a comparative study with acral nevi. J Eur Acad Dermatol Venereol, 30(7):1125-1128.

[25]CoitDG, ThompsonJA, AlgaziA, et al., 2016a. Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 14(4):450-473.

[26]CoitDG, ThompsonJA, AlgaziA, et al., 2016b. NCCN guidelines insights: melanoma, version 3.2016. J Natl Compr Canc Netw, 14(8):945-958.

[27]CoitDG, ThompsonJA, AlbertiniMR, et al., 2019. Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 17(4):367-402.

[28]CostelloCM, GhanavatianS, TemkitM, et al., 2018. Educational and practice gaps in the management of volar melanocytic lesions. J Eur Acad Dermatol Venereol, 32(9):1450-1455.

[29]CurtinJA, FridlyandJ, KageshitaT, et al., 2005. Distinct sets of genetic alterations in melanoma. N Engl J Med, 353(20):2135-2147.

[30]CurtinJA, BusamK, PinkelD, et al., 2006. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol, 24(26):4340-4346.

[31]DarmawanCC, JoG, MontenegroSE, et al., 2019. Early detection of acral melanoma: a review of clinical, dermoscopic, histopathologic, and molecular characteristics. J Am Acad Dermatol, 81(3):805-812.

[32]DeFacto, Eng.LSM.lv, 2019. Rigvir cancer treatment at center of fresh controversy. https://eng.lsm.lv

[33]de Lima VazquezV, VicenteAL, CarloniA, et al., 2016. Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas. Melanoma Res, 26(2):93-99.

[34]DiazA, Puig-ButilléJA, ValeraA, et al., 2014. TERT and AURKA gene copy number gains enhance the detection of acral lentiginous melanomas by fluorescence in situ hybridization. J Mol Diagn, 16(2):198-206.

[35]DobsonR, BurgessMI, ValleJW, et al., 2014. Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality. Br J Cancer, 111(9):1703-1709.

[36]DoniņaS, StrēleI, ProbokaG, et al., 2015. Adapted ECHO-7 virus rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res, 25(5):421-426.

[37]EggermontAMM, BlankCU, MandalaM, et al., 2018. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med, 378(19):1789-1801.

[38]EspadaJ, CalvoMB, Díaz-PradoS, et al., 2009. Wnt signalling and cancer stem cells. Clin Transl Oncol, 11(7):411-427.

[39]FanQ, CohenS, JohnB, et al., 2015. Melanoma in situ treated with topical imiquimod for management of persistently positive margins: a review of treatment methods. Ochsner J, 15(4):443-447.

[40]FariesMB, ThompsonJF, CochranAJ, et al., 2017. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med, 376(23):2211-2222.

[41]FarrowNE, LeddyM, LandaK, et al., 2020. Injectable therapies for regional melanoma. Surg Oncol Clin N Am, 29(3):433-444.

[42]FeltonS, TaylorRS, SrivastavaD, 2016. Excision margins for melanoma in situ on the head and neck. Dermatol Surg, 42(3):327-334.

[43]Fernandez-FloresA, CassarinoDS, 2017. Histopathological diagnosis of acral lentiginous melanoma in early stages. Ann Diagn Pathol, 26:64-69.

[44]FlahertyKT, RobertC, HerseyP, et al., 2012. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med, 367(2):107-114.

[45]FrewSE, SammutSM, ShoreAF, et al., 2008. Chinese health biotech and the billion-patient market. Nat Biotechnol, 26(1):37-53.

[46]FriedlanderP, HodiFS, 2010. Advances in targeted therapy for melanoma. Clin Adv Hematol Oncol, 8(9):619-627.

[47]FukuharaH, InoY, TodoT, 2016. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci, 107(10):1373-1379.

[48]GarbeC, AmaralT, PerisK, et al., 2020. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics ‒ Update 2019. Eur J Cancer, 126:141-158.

[49]GartnerJJ, DavisS, WeiXM, et al., 2012. Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma. BMC Genomics, 13:505.

[50]GreavesWO, VermaS, PatelKP, et al., 2013. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn, 15(2):220-226.

[51]GumastePV, FlemingNH, SilvaI, et al., 2014. Analysis of recurrence patterns in acral versus nonacral melanoma: should histologic subtype influence treatment guidelines? J Natl Compr Canc Netw, 12(12):1706-1712.

[52]HäfligerEM, RamelyteE, ManganaJ, et al., 2018. Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis. Melanoma Res, 28(5):442-450.

[53]HamidO, PuzanovI, DummerR, et al., 2017. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer, 86:37-45.

[54]HanB, HurK, OhnJ, et al., 2020. Acral lentiginous melanoma in situ: dermoscopic features and management strategy. Sci Rep, 10:20503.

[55]HauschildA, GrobJJ, DemidovLV, et al., 2012. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 380(9839):358-365.

[56]HaywardNK, WilmottJS, WaddellN, et al., 2017. Whole-genome landscapes of major melanoma subtypes. Nature, 545(7653):175-180.

[57]HervieuA, RébéC, VégranF, et al., 2013. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J Invest Dermatol, 133(2):499-508.

[58]HuangK, FanJ, MisraS, 2020. Acral lentiginous melanoma: incidence and survival in the United States, 2006‒2015, an analysis of the SEER registry. J Surg Res, 251:329-339.

[59]IdeT, ItoT, Wada-OhnoM, et al., 2021. Preoperative screening CT and PET/CT scanning for acral melanoma: is it necessary? J Clin Med, 10(4):811.

[60]IshiharaY, SaidaT, MiyazakiA, et al., 2006. Early acral melanoma in situ: correlation between the parallel ridge pattern on dermoscopy and microscopic features. Am J Dermatopathol, 28(1):21-27.

[61]ItoH, AokiH, KühnelF, et al., 2006. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst, 98(9):625-636.

[62]ItoT, WadaM, NagaeK, et al., 2015. Acral lentiginous melanoma: who benefits from sentinel lymph node biopsy? J Am Acad Dermatol, 72(1):71-77.

[63]KaufmanHL, KohlhappFJ, ZlozaA, 2015. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov, 14(9):642-662.

[64]KaunitzGJ, CottrellTR, LiloM, et al., 2017. Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Lab Invest, 97(9):1063-1071.

[65]KhayatD, RixeO, MartinG, et al., 2003. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer, 97(8):1941-1946.

[66]Kilinc KaraarslanI, AkalinT, UnalI, et al., 2007. Atypical melanosis of the foot showing a dermoscopic feature of the parallel ridge pattern. J Dermatol, 34(1):56-59.

[67]KimJY, HwangEJ, ChoiM, et al., 2014. Recurrent acral lentiginous melanoma in situ suggesting the field cell theory. Ann Dermatol, 26(6):779-781.

[68]KimSY, KimSN, HahnHJ, et al., 2015. Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma. J Am Acad Dermatol, 72(6):1036-1046.e2.

[69]KirkwoodJM, RichardsT, ZarourHM, et al., 2002. Immunomodulatory effects of high-dose and low-dose interferon α2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer, 95(5):1101-1112.

[70]KongLQ, TanKP, TanHW, et al., 2020. Use of magnetic resonance imaging as a noninvasive technique to identify acral lentiginous melanoma. J Am Acad Dermatol, 83(2):e121-e123.

[71]KoskiA, KangasniemiL, EscutenaireS, et al., 2010. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther, 18(10):1874-1884.

[72]KrausSL, HaenssleHA, 2013. Early detection of cutaneous melanoma by sequential digital dermatoscopy (SDD). J Dtsch Dermatol Ges, 11(6):509-512.

[73]KunishigeJH, BrodlandDG, ZitelliJA, 2012. Surgical margins for melanoma in situ. J Am Acad Dermatol, 66(3):438-444.

[74]KuruppuD, TanabeKK, 2005. Viral oncolysis by herpes simplex virus and other viruses. Cancer Biol Ther, 4(5):524-531.

[75]KwonMR, ChoiSH, JangKT, et al., 2019. Acral malignant melanoma; emphasis on the primary metastasis and the usefulness of preoperative ultrasound for sentinel lymph node metastasis. Sci Rep, 9:15894.

[76]LallasA, KyrgidisA, KogaH, et al., 2015. The BRAAFF checklist: a new dermoscopic algorithm for diagnosing acral melanoma. Br J Dermatol, 173(4):1041-1049.

[77]LeBoitPE, 2000. A diagnosis for maniacs. Am J Dermatopathol, 22(6):556-558.

[78]LeeJH, ChoiJW, KimYS, 2011. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol, 164(4):776-784.

[79]LeeKT, KimEJ, LeeDY, et al., 2016. Surgical excision margin for primary acral melanoma. J Surg Oncol, 114(8):933-939.

[80]LiangWS, HendricksW, KieferJ, et al., 2017. Integrated gen

[81]omic analyses reveal frequent TERT aberrations in acral melanoma. Genome Res, 27(4):524-532.

[82]LichtyBD, BreitbachCJ, StojdlDF, et al., 2014. Going viral with cancer immunotherapy. Nat Rev Cancer, 14(8):559-567.

[83]LinsleyPS, BradshawJ, GreeneJ, et al., 1996. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity, 4(6):535-543.

[84]LiuXY, FangH, ChenHC, et al., 2012. An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation. PLoS ONE, 7(6):e38659.

[85]LlanosS, DanillaS, BarrazaC, et al., 2006. Effectiveness of negative pressure closure in the integration of split thickness skin grafts: a randomized, double-masked, controlled trial. Ann Surg, 244(5):700-705.

[86]LongGV, HauschildA, SantinamiM, et al., 2017a. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med, 377(19):1813-1823.

[87]LongGV, FlahertyKT, StroyakovskiyD, et al., 2017b. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol, 28(7):1631-1639.

[88]LoosemoreMP, Morales-BurgosA, GoldbergLH, 2013. Acral lentiginous melanoma of the toe treated using Mohs surgery with sparing of the digit and subsequent reconstruction using split-thickness skin graft. Dermatol Surg, 39(1 Pt 1):136-138.

[89]MaldonadoJL, FridlyandJ, PatelH, et al., 2003. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst, 95(24):1878-1890.

[90]ManzanoJL, LayosL, BugésC, et al., 2016. Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med, 4(12):237.

[91]MarekAJ, MingME, BartlettEK, et al., 2016. Acral lentiginous histologic subtype and sentinel lymph node positivity in thin melanoma. JAMA Dermatol, 152(7):836-837.

[92]MenisD, Maroñas-JiménezL, Rodríguez-PeraltoJ, et al., 2015. Two Spanish cases of atypical melanosis of the foot, an early stage of acral lentiginous melanoma in situ. Br J Dermatol, 172(5):1436-1438.

[93]MillerDM, FlahertyKT, TsaoH, 2014. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma. Semin Cutan Med Surg, 33(2):60-67.

[94]MunJH, JoG, DarmawanCC, et al., 2018. Association between Breslow thickness and dermoscopic findings in acral melanoma. J Am Acad Dermatol, 79(5):831-835.

[95]NakamuraY, FujisawaY, 2018. Diagnosis and management of acral lentiginous melanoma. Curr Treat Options Oncol, 19(8):42.

[96]NakamuraY, FujisawaY, OkiyamaN, et al., 2018. Surgical damage to the lymphatic system promotes tumor growth via impaired adaptive immune response. J Dermatol Sci, 90(1):46-51.

[97]Ocampo-GarzaJ, di ChiacchioNG, HanekeE, et al., 2017. Subungual melanoma in situ treated with imiquimod 5% cream after conservative surgery recurrence. J Drugs Dermatol, 16(3):268-270.

[98]OgataD, AraiE, GotoY, et al., 2018. Pilot study on the correlation between dermoscopic patterns and fluorescence in situ hybridization findings using whole-slide digital imaging for acral volar melanocytic lesions. J Dermatol, 45(7):830-836.

[99]OhBH, LeeSH, NamKA, et al., 2013. Comparison of negative pressure wound therapy and secondary intention healing after excision of acral lentiginous melanoma on the foot. Br J Dermatol, 168(2):333-338.

[100]OhTS, BaeEJ, RoKW, et al., 2011. Acral lentiginous melanoma developing during long-standing atypical melanosis: usefulness of dermoscopy for detection of early acral melanoma. Ann Dermatol, 23(3):400-404.

[101]OmholtK, GrafströmE, Kanter-LewensohnL, et al., 2011. KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res, 17(12):3933-3942.

[102]OrgazJL, Sanz-MorenoV, 2013. Emerging molecular targets in melanoma invasion and metastasis. Pigment Cell Melanoma Res, 26(1):39-57.

[103]PalmerSR, EricksonLA, IchetovkinI, et al., 2011. Circulating serologic and molecular biomarkers in malignant melanoma. Mayo Clin Proc, 86(10):981-990.

[104]ParkHS, ChoKH, 2010. Acral lentiginous melanoma in situ: a diagnostic and management challenge. Cancers, 2(2):642-652.

[105]PeroneJA, FarrowN, TylerDS, et al., 2018. Contemporary approaches to in-transit melanoma. J Oncol Pract, 14(5):292-300.

[106]PhanA, DalleS, TouzetS, et al., 2010. Dermoscopic features of acral lentiginous melanoma in a large series of 110 cases in a white population. Br J Dermatol, 162(4):765-771.

[107]PolJ, KroemerG, GalluzziL, 2016. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology, 5(1):e1115641.

[108]RafiqueI, KirkwoodJM, TarhiniAA, 2015. Immune checkpoint blockade and interferon-α in melanoma. Semin Oncol, 42(3):436-447.

[109]Rajabi-EstarabadiA, BittarJM, ZhengCW, et al., 2019. Optical coherence tomography imaging of melanoma skin cancer. Lasers Med Sci, 34(2):411-420.

[110]RavaioliGM, DikaE, LambertiniM, et al., 2019. Acral melanoma: correlating the clinical presentation to the mutational status. G Ital Dermatol Venereol, 154(5):567-572.

[111]RibasA, DummerR, PuzanovI, et al., 2017. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell, 170(6):1109-1119.e10.

[112]RidgewayCA, HiekenTJ, RonanSG, et al., 1995. Acral lentigin

[113]ous melanoma. Arch Surg, 130(1):88-92.

[114]RobertC, ThomasL, BondarenkoI, et al., 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med, 364(26):2517-2526.

[115]RobertC, LongGV, BradyB, et al., 2015. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med, 372(4):320-330.

[116]RobinsonC, XuMM, NairSK, et al., 2022. Oncolytic viruses in melanoma. Front Biosci, 27(2):63.

[117]RussoI, ZorzettoL, FrigoAC, et al., 2017. A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience. Eur J Dermatol, 27(5):482-486.

[118]SaidaT, 1989. Malignant melanoma in situ on the sole of the foot. Its clinical and histopathologic characteristics. Am J Dermatopathol, 11(2):124-130.

[119]SaidaT, KogaH, 2007. Dermoscopic patterns of acral melanocytic nevi: their variations, changes, and significance. Arch Dermatol, 143(11):1423-1426.

[120]SaidaT, KogaH, UharaH, 2011. Key points in dermoscopic differentiation between early acral melanoma and acral nevus. J Dermatol, 38(1):25-34.

[121]SankiA, UrenRF, MoncrieffM, et al., 2009. Targeted high-resolution ultrasound is not an effective substitute for sentinel lymph node biopsy in patients with primary cutaneous melanoma. J Clin Oncol, 27(33):5614-5619.

[122]SavareseI, PapiF, D'ErricoA, et al., 2015. Acral lentiginous melanoma treated with topical imiquimod cream: possible cooperation between drug and tumour cells. Clin Exp Dermatol, 40(1):27-30.

[123]ScolyerRA, ThompsonJF, McCarthySW, et al., 2006. Letters to the editor. Australas J Dermatol, 47(1):71-73.

[124]SeegenschmiedtMH, KeilholzL, Altendorf-HofmannA, et al., 1999. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys, 44(3):607-618.

[125]SenzerNN, KaufmanHL, AmatrudaT, et al., 2009. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol, 27(34):5763-5771.

[126]SeoJ, OhY, KimSK, et al., 2021. Slow Mohs micrographic surgery for acral melanoma treatment in Korean patients. Dermatol Surg, 47(2):e42-e46.

[127]SharpeAH, WherryEJ, AhmedR, et al., 2007. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol, 8(3):239-245.

[128]SignorettiS, AnnessiG, PudduP, et al., 1999. Melanocytic nevi of palms and soles: a histological study according to the plane of section. Am J Surg Pathol, 23(3):283-287.

[129]SuJ, YuWJ, LiuJY, et al., 2017. Fluorescence in situ hybridisation as an ancillary tool in the diagnosis of acral melanoma: a review of 44 cases. Pathology, 49(7):740-749.

[130]SwetterSM, TsaoH, BichakjianCK, et al., 2019. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol, 80(1):208-250.

[131]SwetterSM, ThompsonJA, AlbertiniMR, et al., 2021. NCCN Guidelines® insights: melanoma: cutaneous, version 2.2021. J Natl Compr Canc Netw, 19(4):364-376.

[132]TakahashiY, NishikawaM, SueharaT, et al., 2008. Gene silencing of β-catenin in melanoma cells retards their growth but promotes the formation of pulmonary metastasis in mice. Int J Cancer, 123(10):2315-2320.

[133]TaniokaM, 2011. Benign acral lesions showing parallel ridge pattern on dermoscopy. J Dermatol, 38(1):41-44.

[134]TeramotoY, KeimU, GesierichA, et al., 2018. Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. Br J Dermatol, 178(2):443-451.

[135]TodBM, SchneiderJW, BowcockAM, et al., 2020. The tumor genetics of acral melanoma: what should a dermatologist know? JAAD Int, 1(2):135-147.

[136]VirosA, FridlyandJ, BauerJ, et al., 2008. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med, 5(6):e120.

[137]WadaM, ItoT, TsujiG, et al., 2017. Acral lentiginous melanoma versus other melanoma: a single-center analysis in Japan. J Dermatol, 44(8):932-938.

[138]WangWJ, EdingtonHD, RaoUNM, et al., 2007. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNαb. Clin Cancer Res, 13(5):1523-1531.

[139]WeyersW, EulerM, Diaz-CascajoC, et al., 1999. Classification of cutaneous malignant melanoma: a reassessment of histopathologic criteria for the distinction of different types. Cancer, 86(2):288-299.

[140]WollmannG, DavisJN, BosenbergMW, et al., 2013. Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes. J Virol, 87(12):6644-6659.

[141]WoodmanSE, DaviesMA, 2010. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol, 80(5):568-574.

[142]WuXC, EideMJ, KingJ, et al., 2011. Racial and ethnic variations in incidence and survival of cutaneous melanoma in the United States, 1999‒2006. J Am Acad Dermatol, 65(5 Suppl 1):S26.e1-S37.e13.

[143]XuSX, YangZZ, ZhangJY, et al., 2015. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2. DNA Cell Biol, 34(1):69-77.

[144]YamazakiN, TanakaR, TsutsumidaA, et al., 2015. BRAF V600 mutations and pathological features in Japanese melanoma patients. Melanoma Res, 25(1):9-14.

[145]YangTT, YuS, KeCK, et al., 2023. The genomic landscape of melanoma and its therapeutic implications. Genes (Basel), 14(5):1021.

[146]YangZZ, XieL, HuangYC, et al., 2011. Clinical features of malignant melanoma of the finger and therapeutic efficacies of different treatments. Oncol Lett, 2(5):811-815.

[147]YehI, JorgensonE, ShenL, et al., 2019. Targeted genomic profiling of acral melanoma. J Natl Cancer Inst, 111(10):1068-1077.

[148]YorkK, DlovaNC, WrightCY, et al., 2016. Primary cutaneous malignancies in the Northern Cape Province of South Africa: a retrospective histopathological review. S Afr Med J, 107(1):83-88.

[149]ZebaryA, OmholtK, VassilakiI, et al., 2013. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. J Dermatol Sci, 72(3):284-289.

[150]ZemelmanVB, ValenzuelaCY, SazunicI, et al., 2014. Malignant melanoma in Chile: different site distribution between private and state patients. Biol Res, 47:34.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE